Genmab — Januar 2020
-
Daratumumab Plus Rd Sustains Responses in Transplant-Ineligible Myeloma https://www.targetedonc.com/news/daratumumab-plus-rd-sustains-responses-in-transplantineligible-myeloma
-
"....but we are looking at the possibility of re-treatment of daratumumab at this meeting. The concept of the LYNCH trial, which is looking at retreatment of daratumumab at the time of relapse or disease-progression in combination with carfilzomib. While we are going to use daratumumab in the frontline setting, we hope a future study will demonstrate that daratumumab can be reused in the subsequent lines of therapy as well."
-
-
https://www.lifescienceleader.com/doc/current-issue-table-of-contents-0003 Ovenstående fra dette tidsskrift...
-
Rajkumar not impressed with Revlimid Price hike https://twitter.com/vincentrk/status/1213124615922475008?s=21
-
God morgen.
-
Monoclonal antibody-based quadruplet regimen with daratumumab, carfilzomib, lenalidomide, and dexamethasone with MRD–based response-adapted therapy in patients with newly diagnosed MMhttps://multiplemyelomahub.com/medical-information/monoclonal-antibody-based-quadruplet-regimen-with-daratumumab-carfilzomib-lenalidomide-and-dexamethasone-with-mrd-based-response-adapted-therapy-in-patients-with-newly-diagnosed-mm
-
Morn
TA begynder et se interessandt ud efter min mening. Ligger p.t i støtteområde og tæt på bunden i det opadgående trendkanal fra Okt. 2018. Retracement burde snart være et overstået kapitel og stigning op mod/over 1700 ligger i kortene så krydret med lidt godt positivt burde der snart ske noget -
God morgen.
-
God morgen en god nyhed at starte dagen med
Pandora A/SRealtidskurs
Forandring
0%Senest0,00 DKK
Køb
Sælg
Læs mere
GENMAB/JP MORGAN: LØFTER KURSMÅL TIL 1700 KR. OG GENTAGER OVERVÆGT07:19
JP Morgan løfter kursmålet for aktien i Genmab til 1700 kr. fra 1500 kr.Det fremgår af data fra Bloomberg News.
Finanshuset gentager aktieanbefalingen overvægt.
Genmab-aktien faldt 2,8 pct. til 1444,50 kr. fredag.
/ritzau/FINANS
Claus Mikkelsen
RITZAU -
Tusinde tak Duoblo.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind